Disease · MONDO_0018088

familial Mediterranean fever

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. familial Mediterranean fever. Diseases, record MONDO_0018088. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018088

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: familial Mediterranean fever; Open Targets
Open Targets ID: MONDO_0018088; Open Targets
Other names: FMF, Fiebre mediterránea familiar, benign paroxysmal peritonitis, benign recurrent polyserositis, familial paroxysmal polyserositis, periodic disease; Open Targets
Disease Ontology: DOID:2987; Disease Ontology
MeSH: D010505; MeSH
NCI Thesaurus: C84707; NCI Thesaurus
Orphanet: ORPHA:342; Orphanet
Highest stage of its drugs: Approval, for 2 of its 7 drugs, from DailyMed; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CANAKINUMAB	CHEMBL1201834	Antibody	Approval	DailyMed	7	6	6	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Approval	DailyMed	15	3	3	Drugs and targets
ANAKINRA	CHEMBL1201570	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RILONACEPT	CHEMBL1201830	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GOFLIKICEPT	CHEMBL4650513	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VIMNERIXIN	CHEMBL5095217	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IL1B	Interleukin-1 beta	2	Interleukin-1 beta inhibitor	Approval	https://conductscience.org/library/genes/3553	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/3554	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit inhibitor	Phase 2	https://conductscience.org/library/genes/3570	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02059291	Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers	Phase 3	203	2017-03-17	Hereditary Periodic Fevers	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02334748	A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies	Phase 3	31	2020-05-19	Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT00582907	Rilonacept for Treatment of Familial Mediterranean Fever (FMF)	Phase 2	14	2012-10-31	Familial Mediterranean Fever	RILONACEPT	Its record names the disease	ClinicalTrials.gov
NCT00094900	Interleukin-1 Trap to Treat Autoinflammatory Diseases	Phase 2	11	2013-07-10	Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset	RILONACEPT	Its record names the disease	ClinicalTrials.gov
NCT02911857	An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes	Phase 3	4	2018-08-20	Periodic Fevers Syndrome	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT05092776	Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine	Phase 2	84		Familial Mediterranean Fever, FMF	GOFLIKICEPT	Its record names the disease	ClinicalTrials.gov
NCT02602028	The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF	Phase 4	79		Familial Mediterranean Fever	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT01075906	Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients	Phase 1	75		Familial Mediterranean Fever	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT06336733	Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy	Phase 3	50		FMF	ANAKINRA	Its record names the disease	ClinicalTrials.gov
NCT04303689	Repurposing Colchicine to Improve Vascular Function in Hypertension	Not applicable	31		Essential Hypertension	COLCHICINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Rilonacept vs Placebo: serious adverse events	3 of 13	3 of 14	27	NCT00582907

Source Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25049046	RESULT	1	PubMed
23070486	RESULT	1	PubMed
37668289	DERIVED	1	PubMed
36764326	DERIVED	1	PubMed
34554243	DERIVED	1	PubMed
29768139	DERIVED	1	PubMed
27860460	DERIVED	1	PubMed
27055417	DERIVED	1	PubMed
26337145	DERIVED	1	PubMed
25147819	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018088

GET https://conductscience.org/api/diseases/v1/MONDO_0018088/drugs

API reference For AI assistants